company background image
RXDX

Prometheus Biosciences NasdaqGS:RXDX Stock Report

Last Price

US$113.66

Market Cap

US$5.3b

7D

-4.6%

1Y

216.4%

Updated

01 Feb, 2023

Data

Company Financials +

Prometheus Biosciences, Inc.

NasdaqGS:RXDX Stock Report

Mkt Cap: US$5.3b

RXDX Stock Overview

Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD).

RXDX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Prometheus Biosciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Prometheus Biosciences
Historical stock prices
Current Share PriceUS$113.66
52 Week HighUS$122.75
52 Week LowUS$21.50
Beta0
1 Month Change3.33%
3 Month Change128.74%
1 Year Change216.43%
3 Year Changen/a
5 Year Changen/a
Change since IPO349.43%

Recent News & Updates

Here's Why We're Not Too Worried About Prometheus Biosciences' (NASDAQ:RXDX) Cash Burn Situation

Dec 03
Here's Why We're Not Too Worried About Prometheus Biosciences' (NASDAQ:RXDX) Cash Burn Situation

Recent updates

Here's Why We're Not Too Worried About Prometheus Biosciences' (NASDAQ:RXDX) Cash Burn Situation

Dec 03
Here's Why We're Not Too Worried About Prometheus Biosciences' (NASDAQ:RXDX) Cash Burn Situation

We Think Prometheus Biosciences (NASDAQ:RXDX) Needs To Drive Business Growth Carefully

Aug 19
We Think Prometheus Biosciences (NASDAQ:RXDX) Needs To Drive Business Growth Carefully

We're Hopeful That Prometheus Biosciences (NASDAQ:RXDX) Will Use Its Cash Wisely

May 04
We're Hopeful That Prometheus Biosciences (NASDAQ:RXDX) Will Use Its Cash Wisely

Prometheus Biosciences (NASDAQ:RXDX) Is In A Good Position To Deliver On Growth Plans

Nov 16
Prometheus Biosciences (NASDAQ:RXDX) Is In A Good Position To Deliver On Growth Plans

Shareholder Returns

RXDXUS BiotechsUS Market
7D-4.6%-0.2%1.7%
1Y216.4%3.9%-12.5%

Return vs Industry: RXDX exceeded the US Biotechs industry which returned 1.2% over the past year.

Return vs Market: RXDX exceeded the US Market which returned -13.6% over the past year.

Price Volatility

Is RXDX's price volatile compared to industry and market?
RXDX volatility
RXDX Average Weekly Movement48.4%
Biotechs Industry Average Movement12.3%
Market Average Movement6.9%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: RXDX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 48% a week.

Volatility Over Time: RXDX's weekly volatility has increased from 25% to 48% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201672Mark McKennahttps://www.prometheusbiosciences.com

Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn’s disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; PR1800, an anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD.

Prometheus Biosciences, Inc. Fundamentals Summary

How do Prometheus Biosciences's earnings and revenue compare to its market cap?
RXDX fundamental statistics
Market CapUS$5.28b
Earnings (TTM)-US$132.91m
Revenue (TTM)US$7.19m

734.6x

P/S Ratio

-39.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RXDX income statement (TTM)
RevenueUS$7.19m
Cost of RevenueUS$106.47m
Gross Profit-US$99.28m
Other ExpensesUS$33.63m
Earnings-US$132.91m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.86
Gross Margin-1,380.19%
Net Profit Margin-1,847.71%
Debt/Equity Ratio0%

How did RXDX perform over the long term?

See historical performance and comparison